Esmethadone in Major Depressive Disorder: Pharmacology and Clinical Evidence

Major Depressive Disorder (MDD) affects approximately 280 million people globally, with current treatments showing significant limitations, including delayed onset of action, low remission rates, and troublesome side effects. Esmethadone (REL-1017, d-methadone) has emerged as a promising agent for MDD. This review examines esmethadone (REL-1017), a novel glutamatergic modulator functioning primarily as an N-methyl-D-aspartate (NMDA) receptor antagonist with minimal opioid receptor activity. Unlike conventional antidepressants, esmethadone demonstrates a rapid onset of antidepressant effects within days rather than weeks. Clinical evidence from Phase 2 and 3 trials suggests promising efficacy as both monotherapy and adjunctive treatment, with significant reductions in depression severity compared to placebo. Esmethadone offers potential advantages over both traditional antidepressants (faster onset, different side effect profile) and other rapid-acting agents like ketamine (oral administration, minimal dissociative effects, no monitoring requirements). For patients requiring a more rapid response than traditional antidepressants provide but unable or unwilling to undergo ketamine or esketamine treatment, esmethadone may represent a valuable option. Notably, esmethadone’s oral administration and minimal dissociative effects make it a compelling outpatient alternative to ketamine-based therapies. The Phase 3 program for esmethadone, designated RELIANCE, consists of three pivotal trials and an open-label extension study. RELIANCE-I evaluated esmethadone as adjunctive therapy in patients with MDD who had an inadequate response to standard antidepressants. RELIANCE-II focused on esmethadone as monotherapy and demonstrated statistically significant improvements in MADRS. RELIANCE-III, still ongoing as of October 2024, is evaluating esmethadone specifically in patients with TRD, with a longer treatment duration (8 weeks) to assess sustained efficacy in this difficult-to-treat population. The RELIANCE-OLE (open-label extension) study is providing long-term safety and efficacy data. With a favorable tolerability profile and once-daily oral dosing, esmethadone may represent an important therapeutic advance for MDD patients, particularly those with inadequate responses to conventional treatments. Regulatory submissions are anticipated in early 2025, with ongoing research addressing long-term efficacy, safety in special populations, and potential applications beyond MDD. Further research addressing the identified knowledge gaps will help optimize esmethadone's use and maximize its potential benefit for patients with this disabling psychiatric condition.